Zobrazeno 1 - 10
of 81
pro vyhledávání: '"D Bracy"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D. Siegel, Guido Tricot, D Bracy, K. R. Desikan, Sundar Jagannath, Nikhil C. Munshi, Clive S. Zent, Carla S. Wilson, Bart Barlogie, Anthony W. Butch
Publikováno v:
Blood. 91:3518-3523
Multiple myeloma (MM) is usually characterized by production of a single serum monoclonal protein of constant isotype and light-chain restriction. Multiple Ig isotypes and isotype switches, which are rare in untreated patients, are reported to be mor
Autor:
D. Siegel, Seema Singhal, S Mattox, Nikhil C. Munshi, Jayesh Mehta, J Nelson, S Tindle, Bart Barlogie, A. Fassas, D Bracy, K. R. Desikan, Guido Tricot, David H. Vesole, Sundar Jagannath
Publikováno v:
Journal of Clinical Oncology. 16:1547-1553
PURPOSE To compare, in the setting of tandem autotransplantations for multiple myeloma (MM), two established methods of peripheral-blood stem-cell (PBSC) procurement with chemotherapy or hematopoietic growth factor alone. PATIENTS AND METHODS Between
Publikováno v:
Leukemia & Lymphoma. 28:501-508
Reinfusion of mobilized peripheral blood stem cells (PBSC) after high dose chemotherapy accelerates hematopoietic recovery. Because of the relatively low content of hematopoietic progenitors in the peripheral blood even after mobilization, multiple l
Autor:
Sundar Jagannath, David A. Siegel, S. Naucke, Jeffrey R. Sawyer, Bart Barlogie, K. R. Desikan, S Mattox, Nikhil C. Munshi, D Bracy, Guido Tricot
Publikováno v:
Journal of Clinical Oncology. 15:2659-2666
PURPOSE Although important predictors of survival in myeloma patients have been identified, it is well recognized that better prognostic factors for this disease are needed. Because cytogenetics play a dominant role in the outcome of patients with ac
Autor:
Sydney E. Salmon, Bruce D. Cheson, John Crowley, S Mattox, Guido Tricot, S. Naucke, D Bracy, Joth Jacobson, David H. Vesole, Bart Barlogie, Sundar Jagannath
Publikováno v:
Blood. 89:789-793
Virtually no progress has been made during more than 2 decades of clinical trials for multiple myeloma (MM) involving standard therapy (ST). Recent studies suggest that dose intensification requiring hematopoietic stem cell support results in higher
Autor:
Wanda D. Bracy
Publikováno v:
Journal of Baccalaureate Social Work. 2:43-62
This article provides a typology of approaches to the inclusion of diversity in the curriculum and a discussion of the issues and concerns in the development of an inclusive curriculum. The typology consists of two broad dimensions that underlie vari
Autor:
D Bracy, Bruce Cheson, K. R. Desikan, John Crowley, Sundar Jagannath, Bart Barlogie, Langdon Miller, David H. Vesole, Guido Tricot, D. Siegel
Publikováno v:
Blood. 88:838-847
Of 496 consecutive patients with multiple myeloma (MM) enrolled in clinical trials of tandem transplants with peripheral blood stem cells support, 470 (95%) completed the first autotransplant with melphalan 200 mg/m2 (MEL 200) and 363 (73%) completed
Autor:
Sundar Jagannath, David H. Vesole, Guido Tricot, S. Naucke, D Bracy, Jeffery R. Sawyer, Bart Barlogie, S Mattox
Publikováno v:
Blood. 86:4250-4256
Chromosomal abnormalities have major biologic and prognostic implications in leukemias. Cytogenetic information in typically hypoproliferative multiple myeloma (MM) is limited because of difficulties in obtaining analyzable metaphases. In this study,